Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$2.19 CAD
Change Today -0.07 / -3.10%
Volume 136.1K
NTB On Other Exchanges
Symbol
Exchange
NASDAQ CM
Berlin
Toronto
As of 3:59 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

neptune tech & bioressources (NTB) Snapshot

Open
C$2.27
Previous Close
C$2.26
Day High
C$2.27
Day Low
C$2.13
52 Week High
06/19/14 - C$3.15
52 Week Low
10/14/14 - C$1.26
Market Cap
165.0M
Average Volume 10 Days
231.8K
EPS TTM
C$-0.30
Shares Outstanding
75.4M
EX-Date
07/24/08
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NEPTUNE TECH & BIORESSOURCES (NTB)

Related News

No related news articles were found.

neptune tech & bioressources (NTB) Related Businessweek News

No Related Businessweek News Found

neptune tech & bioressources (NTB) Details

Neptune Technologies & Bioressources Inc., a biotechnology company, focuses on the research, development, and commercialization of products derived from marine biomasses for the nutraceutical and pharmaceutical industries. It produces marine-derived omega-3 polyunsaturated fatty acids, including Neptune Krill Oil (NKO), a dietary supplement for heart, joint, women, and brain health; ECOKRILL Oil (EKO), a krill product; and Neptune Krill Aquatein (NKA), a protein ingredient used in the production of nursing feed for young animals. The company is also developing CaPre, which is in Phase II clinical trials for the management of mild to moderate hypertriglyceridemia and severe hypertriglyceridemia, as well as develops and commercializes pharmaceutical applications for cardiovascular and neurological diseases. Neptune Technologies & Bioressources sells its products in Canada, the United States, France, Belgium, Australia, and other countries. The company was founded in 1925 and is headquartered in Laval, Canada.

126 Employees
Last Reported Date: 01/13/15
Founded in 1925

neptune tech & bioressources (NTB) Top Compensated Officers

Chief Financial Officer
Total Annual Compensation: C$164.1K
Consulting Medical Science Liaison
Total Annual Compensation: C$196.0K
Senior Vice-President of Global Sales
Total Annual Compensation: C$175.2K
Compensation as of Fiscal Year 2014.

neptune tech & bioressources (NTB) Key Developments

Neptune Technologies & Bioressources, Inc. Presents at 27th Annual ROTH Conference, Mar-10-2015 04:30 PM

Neptune Technologies & Bioressources, Inc. Presents at 27th Annual ROTH Conference, Mar-10-2015 04:30 PM. Venue: The Ritz Carlton, 1 Ritz Carlton Dr, Dana Point, CA 92629, United States. Speakers: Andre Godin, Chief Financial Officer.

Neptune Technologies & Bioressources, Inc. Announces Transition of Tina Sampalis from Chief Global Strategic Officer to Medical Science Liaison

Neptune Technologies & Bioressources, Inc. and Acasti Pharma Inc. announced the transition of Dr. Tina Sampalis from Chief Global Strategic Officer to a consulting role as Medical Science Liaison for Neptune, starting immediately.

Neptune Technologies & Bioressources Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended November 30, 2014

Neptune Technologies & Bioressources Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended November 30, 2014. For the quarter, the company reported net income of $74,000, versus a net loss of $10.4 million in the year ago quarter. Revenues were $4.7 million, up 4% from $4.5 million reported for the same period last year. Adjusted EBITDA was negative $4,315,000 for the current quarter, versus negative $5,912,000 in the prior year. The quarterly net income for the current quarter was derived by the nutraceutical gains, along with an increase in finance income attributable to the re-evaluation of the warrant liabilities related to Acasti's December 2013 public offering. Net loss attributable to the owners of the corporation was $1.33 million against $8.8 million a year ago. Basic and diluted loss per share was $0.02 against $0.14 a year ago. Revenues for the quarter were slightly higher than last year given that Neptune restarted its plant operations in the previous quarter, and despite being in a ramp-up period for most of the quarter, Neptune managed to complete the quarter at full capacity allowing the corporation to proceed with NKO shipments mainly towards the second half of the quarter. Loss from operating activities was $5.83 million against $10 million a year ago. Income before income taxes was $0.073 million against loss of $10.44 million a year ago. Cash flow used in operating activities was $8.89 million against $8.09 million a year ago. Acquisition of property, plant and equipment was $1.83 million against $4.27 million a year ago. Acquisition of intangible assets was $6,673 against negative of $66,843 a year ago. For the nine months, the company reported revenues of $11,049,000 compared to $15,906,000 for the corresponding prior-year period. Adjusted EBITDA was negative $22,962,000 for the nine-month period ended November 30, 2014, versus negative $15,951,000 for the corresponding prior-year period. Net loss was $19,143,000 for the nine-month period ended November 30, 2014, versus a net loss of $20,910,000 in the corresponding prior-year period. Net loss attributable to the owners of the corporation was $18.74 million against $16.83 million a year ago. Basic and diluted loss per share was $0.25 against $0.28 a year ago. During the nine-month periods ended November 30, 2014, the operating activities generated a decrease in liquidities of $15,262, compared to a decrease of $15,293 for the corresponding nine-month period ended November 30, 2013. Cash flow used in operating activities was $15.71 million against $15.29 million a year ago. Acquisition of property, plant and equipment was $16.38 million against $7.53 million a year ago. Acquisition of intangible assets was $88,924 against $247,924 a year ago. The decrease in the cash flows from the operating activities for the nine-month period ended November 30, 2014 is mainly attributable to the higher loss from operating activities offset by the changes in non-cash operating working capital items, primarily by a large decrease in trade and other receivables of $11,015 offset by an increase in inventories of $6,225. Loss from operating activities was $28.29 million against $20.58 million a year ago. Loss before income taxes was $18.9 million against loss of $20.91 million a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NTB:CN C$2.19 CAD -0.07

NTB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Apator SA 44.00 PLN -0.13
Badger Meter Inc $61.61 USD +0.01
Enzymotec Ltd $9.18 USD -0.07
Itron Inc $36.50 USD -0.73
Targeted Medical Pharma Inc $0.10 USD +0.04
View Industry Companies
 

Industry Analysis

NTB

Industry Average

Valuation NTB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.8x
Price/Book 2.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEPTUNE TECH & BIORESSOURCES, please visit www.neptunebiotech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.